Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
9.17 Influence of Non-Haemodynamic Factors on Left Ventricular Mass in Adolescents with High Prevalence of Obesity: the Strong Heart Study
-
Article
7.2 Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients during Anti-Hypertensive Treatment: the Life Study
-
Article
9.8 New-Onset Diabetes and Uncontrolled Blood Pressure
-
Article
5.19 Correlation Among Renal and Cardiac Function and Left Ventricular Geometries: The Strong Heart Study
-
Article
11.8 Addition of Canrenone to Optimal Therapy Improves Cardiac Geometry and Function in Patients with Systolic Heart Failure and Metabolic Syndrome: the AREA-IN-CHF Study
-
Article
9.26 Diagnosis of Metabolic Syndrome Based on History of Exposure or Present Abnormalities: Evidence of Necessity of a Better Definition
-
Article
9.29 Diabetes and Incident Heart Failure: the Strong Heart Study
-
Article
5.18 Cardiovascular and Metabolic Predictors of Progression to Overt Hypertension in a Population with Basal High-Normal Blood Pressure Levels: The Strong Heart Study
-
Article
2.18 Interaction of Metabolic Syndrome and Left Ventricular Hypertrophy in the Prediction of Cardiovascular Risk: the Strong Heart Study
-
Article
4.13 Left Atrial Volume and Ventricular Filling Pattern in Mild Heart Failure: The AREA-IN-CHF Study
-
Article
4.15 Elevated B-Type Natriuretic Peptide Indicates Increased End-Diastolic Pressure in Patients with Mild-Moderate Heart Failure and Systolic Dysfunction: The AREA-IN-CHF Study
-
Article
4.21 Metabolic Syndrome and Left Ventricular Function in Mild Heart Failure: The AREA-IN-CHF Study
-
Article
2.17 Incident Arterial Hypertension and Left Ventricular Mass in the Presence of Initial Optimal Blood Pressure: the Strong Heart Study